
<h3>Mission</h3>

<p>To further the Strategic Plan by advocating AGA research, clinical and reimbursement/payment policies; lobbying Congress
    and federal regulatory agencies regarding gastroenterologists&rsquo; place in health-care delivery; and to influence
    a favorable outcome of proposed and existing regulations as well as new, proactive initiatives.</p>


<h3>Committee Structure</h3>

<p>The committee shall consist of 10 members (including a chair), plus a trainee. The members will possess specific skill sets
    to ensure that the committee can effectively deliberate the many complex issues that are under its purview. The chairs
    of the AGA Institute Practice Management and Economics Committee, AGA PAC Board of Advisors, AGA Institute Quality Measures
    Committee and AGA Institute Research Policy Committees, and AGA&rsquo;s delegates to the AMA (who shall not count against
    the maximum membership), shall serve as non-voting,
    <em>ex-officio</em> members. A practice councillor (who shall not count against the maximum membership) shall serve as the
    governing board&rsquo;s liaison to the committee and shall attend all committee meetings; additional members of the governing
    board (who shall not count against the maximum membership) may be assigned as team members to the committee but are not
    intended to attend any committee meetings. A chair-elect (who shall not count against the maximum membership) shall be
    appointed one year before the end of the term of the chair.</p>

<p>Appointment terms of all committee members shall be for two years, with the opportunity to be renewed for an additional year
    based on attendance and performance. One-third of the maximum terms will expire annually.</p>

<h4>Subcommittee Structure</h4>

<p>There shall be at least one subcommittee that will report to the chair of the AGA Government Affairs Committee. The structure
    and mission of the subcommittee is as follows:</p>

<h5>AGA Research Advocacy Subcommittee.</h5>

<p>Responsibilities include monitoring federal legislative and agency activities related to digestive disease research, and
    recommending policies and initiatives to advance such research.</p>

<p>The subcommittee will be chaired by a member of the AGA Government Affairs Committee and may be populated by both members
    and nonmembers of the full committee. Costs of the subcommittee must be included in the committee&rsquo;s approved budget.</p>

<h3>Special Qualifications and Functions, Committee Chair</h3>

<ul>
    <li>Familiarity with biomedical research funding, clinical practice payment issues and the federal legislative and regulatory
        processes.</li>
    <li>Recent experience as a member of the AGA Government Affairs Committee or comparable committee in another organization.</li>
</ul>

<h3>Special Qualifications and Functions, Committee Member</h3>

<p>The make-up of the committee shall have the following member skill sets:</p>

<ul>
    <li>Solid practice management experience; understands business-side of running a practice; understands how practices are
        changing to reflect the current marketplace (MACRA; consolidation of practices; development of ACOs; impact of health-care
        reform on practices, etc.).</li>
    <li>h6 reimbursement and coding experience; insights into the future of practice (procedures; upcoming technologies).</li>
    <li>Knowledge of FDA processes and issues.</li>
    <li>Involved in biomedical research; understands inner workings of NIH and other research agencies.</li>
    <li>Health information technology experience (EHRs; e-prescribing; MIPS as it applies to EHRs).</li>
    <li>In large group practice (does procedures in office, HOPD and ASC settings).</li>
    <li>In solo or small-group practice (does procedures in office, HOPD and ASC settings).</li>
    <li>A young physician who can provide perspective of challenges to young GIs.</li>
    <li>A quality background (understands clinical measures, MIPS and APMs, comparative effectiveness).</li>
    <li>Practice manager.</li>
</ul>


<h3>Committee Functions</h3>

<h6>The committee will:</h6>

<ul>
    <li>Implement relevant strategic directions from the Strategic Plan assigned to the committee, and review the Strategic Plan
        to determine new and better ways to achieve association goals.</li>
    <li>Provide input on strategic trends and opportunities and suggest adjustments to the Strategic Plan.</li>
    <li>Regularly review public health issues and AGA policies to determine those suitable for federal legislative or regulatory
        initiatives; periodically survey members to determine problems or opportunities suitable for federal legislative
        or regulatory initiatives.</li>
    <li>Regularly review the Strategic Plan to identify federal legislative or regulatory initiatives.</li>
    <li>Translate AGA policies, problems, opportunities and strategic directions into specific legislative or regulatory vehicles.</li>
    <li>Develop and implement lobbying and related advocacy programs to secure action on legislative or regulatory vehicles.</li>
    <li>Propose annual budgets necessary to achieve legislative and regulatory goals and operate within the approved budget.</li>
    <li>Implement public policy efforts as prioritized by the governing board.</li>
    <li>Collaborate with the AGA PAC Board of Advisors and research advocacy subcommittee on the development of grassroots advocacy
        strategies.</li>
    <li>Communicate on an ongoing basis with members to motivate members to action and to inform them of AGA activities.</li>
    <li>Develop and maintain a program to motivate and support members who wish to contact or engage legislators and regulators
        in support of the AGA legislative program.</li>
    <li>Increase name recognition for AGA among key influential audiences.</li>
    <li>Perform other functions as assigned by the governing board.</li>
</ul>

<h3>Meetings</h3>

<p>The committee is authorized to hold two face-to-face meetings per year, one in September and one at DDW, and teleconferences
    as needed.</p>

<p>The subcommittee will largely conduct business via teleconferences and email list servs but may be required to meet at DDW
    or in September.</p>

<h3>Members</h3>

<ul>
    <li>Peter S. Margolis, MD, AGAF (chair)</li>
    <li>Lisa M. Gangarosa, MD, AGAF (chair-elect)</li>
    <li>Steven L. Carpenter, MD, AGAF</li>
    <li>Ziad F. Gellad, MD, MPH, AGAF</li>
    <li>Johannes Koch, MD, AGAF</li>
    <li>Joseph Losurdo, MD, AGAF</li>
    <li>Kathy J. Sammis</li>
    <li>Thomas J. Shireman, MD</li>
    <li>Gaurav Singhvi, MD</li>
    <li>Bertha E. Toriz, MD</li>
    <li>G. Nicholas Verne, MD, AGAF</li>
    <li>Stephanie D. Pointer, MD (trainee member)</li>
    <li>Megan A. Adams, MD, JD, MSc (ex-officio)</li>
    <li>Stephen W. Hiltz, MD, MBA, AGAF (ex-officio)</li>
    <li>Peter Kaufman, MD, AGAF (ex-officio)</li>
    <li>Anil K. Rustgi, MD, AGAF (ex-officio)</li>
    <li>Sarah E. Streett, MD, AGAF (ex-officio)</li>
    <li>F. Taylor Wootton III, MD, AGAF (ex-officio)</li>
</ul>

<p align="right">
    <a href="#top" target="_top">
        <small>Back to Top</small>
    </a>
</p>